[HTML][HTML] ERBB3 Overexpression is Enriched in Diverse Patient Populations with Castration-sensitive Prostate Cancer and is Associated with a Unique AR Activity …
JE Vellky, BJ Kirkpatrick, LC Gutgesell, M Morales… - Clinical Cancer …, 2024 - AACR
Purpose: Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer is only …
ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature.
JE Vellky, BJ Kirkpatrick, LC Gutgesell… - … Cancer Research: an …, 2024 - europepmc.org
Purpose Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer (CRPC) is …
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer (CRPC) is …
ERBB3 overexpression is enriched in diverse patient populations with castration-sensitive prostate cancer and is associated with a unique AR activity signature
JE Vellky, BJ Kirkpatrick, LC Gutgesell… - … cancer research: an … - pubmed.ncbi.nlm.nih.gov
Purpose Despite successful clinical management of castration-sensitive prostate cancer
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer (CRPC) is …
(CSPC), the 5-year survival rate for men with castration-resistant prostate cancer (CRPC) is …